Consider using CGM to assess glycaemic response to foods (especially if you were glucose dysregulated before) Expected outcomes: Appetite reduction, 25% waist circumference and weight loss, early visceral fat reduction, improved post-meal glucose responses Month 35: Acceleration Phase Reach therapeutic steady GLP-1 dose Use CGM data to guide food choices where necessary Resistance training becomes part of routine and needs to be progressive (ie once strength improves and it becomes easy, lift heavier weights) Waist circumference continues to drop, even if weight remains steady (as muscle weighs more than adipose tissue) Likely improvement in glycaemic and MASLD blood markers Expected outcomes: 510% total body weight loss, increased insulin sensitivity, improved energy levels, lowered blood pressure Month 68: Transition Phase Emphasis shifts to muscle preservation and metabolic independence Protein intake and strength training remain central For those reaching waist goals, begin tapering GLP-1 dose under supervision Expected outcomes: Stable lean mass, reduced visceral fat, better metabolic flexibility, readiness to stop medication How Do We Measure Success
ZEPBOUND has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5.5)]
However, it is important to let your provider know if you are experiencing any gastrointestinal symptoms, including but not limited to: liver problems such as hepatitis
En el Nurses Health Study se demostr que la obesidad per se incrementa cinco veces el riesgo de muerte por causa cardiovascular en las mujeres (2) y en el estudio alemn PROCAM ( Prospective Cardiovascular Munster study ), en el cual se reclutaron ms de ocho mil mujeres, se observ que a medida que aumenta el IMC todos los factores de riesgo cardiovascular (FRCV) aumentan su prevalencia (3) (Fig
Label: Wegovy- semaglutide injection, solution
